Income Statement
MAINZ BIOMED N.V.
QUCY
Performance Overview
Click any row in the table to add it to this chart
in millions USD
| Metric | Dec 31, 2025 2025 FY |
|---|---|
|
Revenue
|
0.54 |
|
Cost of Revenue
|
0.15 |
|
Gross Profit
|
0.39 |
|
Operating Expenses
|
16.53 |
|
Research & Development
|
4.91 |
|
Selling, General & Administrative
|
5.11 |
|
Other Operating Expenses
|
- |
|
Operating Income
|
-16.14 |
|
Non-Operating Income
|
-0.07 |
|
Interest Income
|
- |
|
Interest Expense
|
0.08 |
|
Other Non-Op Income / Expense
|
- |
|
Income Before Tax
|
-16.21 |
|
Income Tax Expense
|
0.00 |
|
Non-Controlling Interest
|
- |
|
Net Income
|
-16.21 |
Supplemental
Per share data, derived & other items — not part of the income statement
in millions USD unless noted
| Metric | Dec 31, 2025 2025 FY |
|---|---|
|
Depreciation & Amortization
|
- |
|
EBITDA
|
-15.52 |
|
Earnings Per Share (Basic)
|
-2.70 |
|
Diluted EPS
|
-2.70 |
|
Weighted Average Shares
|
6.00 |
|
Diluted Weighted Avg Shares
|
6.00 |
|
Comprehensive Income
|
-16.28 |